Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verorab immunogenicity and safety after one-week 4-site intradermal PEP and 5-year booster
2018-004707-40Phase 3
- Sponsor
- Sanofi
- Start
- Feb 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rabies virus inactivated antigen, A in rabies (2 arms), sponsored by Sanofi. Primary endpoint: Seroconversion at Day 14.
02
Drugs
rabies virus inactivated antigen, A
03
Conditions
rabies
Beyond the preview
Go deeper on 2018-004707-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004707-40.